| Literature DB >> 29534008 |
Monica Currò1, Tiziana Russo2, Nadia Ferlazzo3, Daniela Caccamo4, Pietro Antonuccio5, Salvatore Arena6, Saveria Parisi7, Patrizia Perrone8, Riccardo Ientile9, Carmelo Romeo10, Pietro Impellizzeri11.
Abstract
Balanitis xerotica obliterans (BXO) is a chronic inflammatory skin disorder, considered the male genital variant of lichen sclerosus. Anti-inflammatory drugs are commonly used in BXO. We evaluated the effects of an innovative formulation of ozonated olive oil with vitamin E acetate (OZOILE®) on the inflammatory status and tissue remodeling in male children with BXO. The mRNA transcripts of proteins involved either in inflammation or in dynamics of tissue regeneration were analyzed by quantitative real-time PCR, in foreskins affected by BXO removed from patients untreated or treated with OZOILE® cream for 7 days before circumcision. We found a significant reduction in mRNA levels of IL-1β, TNF-α, INF-γ, transglutaminase 2 and NOS2 in foreskins treated with OZOILE® in comparison to untreated ones (p < 0.001). No significant differences were observed in NF-κB activation in the specimens obtained from treated and untreated patients. Hence, OZOILE® treatment up-regulated hypoxia-inducible factor (HIF)-1alpha, vascular endothelial growth factor (VEGF) and E-cadherin gene expression (p < 0.001). The treatment with OZOILE® showed effective results in children affected by BXO by reducing the inflammatory process and stimulating mechanisms for tissue regeneration of the foreskin. A randomized clinical trial on a large number of children affected by BXO might be useful to verify the efficacy of topical treatment with OZOILE®.Entities:
Keywords: HIF-1 alpha; antioxidant therapy; balanitis xerotica obliterans; inflammation; ozonated olive oil; tissue regeneration; vitamin E acetate
Mesh:
Substances:
Year: 2018 PMID: 29534008 PMCID: PMC6017296 DOI: 10.3390/molecules23030645
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Changes in mRNA levels of cytokines in foreskin tissues from patients with balanitis xerotica obliterans (BXO) untreated or treated with OZOILE®. The results are the means of data obtained from 15 untreated patients and 15 treated patients. Error bars represent standard error of the mean (SEM). *** p < 0.001 significant differences in comparison with untreated patients.
Figure 2Transcript levels of TG2 (A) and NOS2 (B) in foreskin tissues from patients with BXO untreated or treated with OZOILE®. Results from real-time PCR are expressed as relative fold change compared with foreskin from untreated patients. The data are the means ± standard error of the mean (SEM). *** p < 0.001 significant differences in comparison with untreated patients.
Figure 3Analysis of NF-κB activation in nuclear extracts from foreskins of BXO patients untreated or treated with OZOILE®. DNA binding activity of NF-κB was determined by the electrophoretic mobility shift assay (EMSA). This picture is representative of foreskin tissues from untreated (n = 15) and treated (n = 15) patients. The densitometric analysis of all samples is also reported. The results are expressed as mean ± SEM.
Figure 4Changes in mRNA levels of VEGF and HIF-1α in foreskin tissues from patients with BXO untreated or treated with OZOILE®. The results are the means of data obtained from 15 untreated patients and 15 treated patients. Error bars represent standard error of the mean (SEM). *** p< 0.001 significant differences in comparison with untreated patients.
Figure 5Analysis of expression levels of E-cadherin in foreskins from BXO patients untreated (n = 15) or treated (n = 15) with OZOILE®. Results obtained by real-time PCR are expressed as relative fold change compared with untreated patients. Error bars represent standard error of the mean. *** p<0.001 significant differences in comparison with untreated patients.
qRT-PCR primer sequences.
| Gene | Forward Primer (5′→3′) | Reverse Primer (5′→3′) |
|---|---|---|
| TGGTTACAGGAAGTCCCTTGCC | ATGCTATCACCTCCCCTGTGTG | |
| GCTTATTACAGTGGCAATGA | TAGTGGTGGTCGGAGATT | |
| GTGAGGAGGACGAACATC | GAGCCAGAAGAGGTTGAG | |
| GCAGCCAACCTAAGCAAGAT | TCACCTGACACATTCAAGTTCTG | |
| CCTTACGGAGTCCAACCTCA | CCGTCTTCTGCTCCTCAGTC | |
| TGACCTCCTAACAAGTAGCA | CAGCAGCAAGTTCCATCT | |
| CGTTCCTTCGATCAGTTGTC | TCAGTGGTGGCAGTGGTAGT | |
| AGGAGGAGGGCAGAATCATCA | CTCGATTGGATGGCAGTAGCT | |
| TGAGTGTCCCCCGGTATCTTC | CAGTATCAGCCGCTTTCAGATTTT |